Not medical advice. Talk to your provider before using any peptide. Full disclaimer
BPC-157
Beginner tier: 250 mcg, 2x daily · 6w on / 2w off · community consensus
Also known as: BPC-157, BPC 157, Body Protection Compound
Get an alert when FDA rules on BPC-157
Follow every legal or FDA change, BPC-157 included. By default, alerts come as one weekly push that names the peptides.
Over 220 PubMed papers and years of community reports, but only about 80 people across five small human studies. The BPC-157 peptide (Body Protection Compound-157) is a 15-amino-acid pentadecapeptide from human gastric juice. It has become the most discussed healing peptide online, with reliable community reports of accelerated tendon, ligament, and gut repair. Animal research backs the mechanism. The standard protocol (250 mcg subcutaneous twice daily near the injury) has been stable for years. Community evidence is strong; formal clinical proof is still catching up fast.
What Is BPC-157?
A 2025 systematic review by Vasireddi's group [1] screened 544 papers on BPC-157. Thirty-six met inclusion criteria. Thirty-five were preclinical studies. One was clinical. That ratio says a lot about where the science stands right now. The review's orthopaedic search ran through June 3, 2024, and kept studies of mechanism, musculoskeletal outcomes, metabolism and safety. FDA's July 2026 briefing searched every use and counted five small human studies, two known only from meeting abstracts.
The BPC-157 peptide (Body Protection Compound-157) is a pentadecapeptide (15 amino acids) from a protective protein in human gastric juice. In animal and cell studies, it promotes tissue repair through angiogenesis (VEGF-driven blood vessel growth), nitric oxide modulation, and FAK-paxillin pathway activation in tendon cells. One property separates it from most peptides: it stays stable in human gastric juice [6]. In rats, oral dosing works for gut injuries; no human study has measured how much of an oral dose is absorbed.
Animal data is reproducible across labs and species. Healing acceleration has been confirmed in tendons, ligaments, muscles, nerves, corneas, and intestinal ulcers. A 2024 intravesical case series (12 patients (n=12) with interstitial cystitis) reported 80 to 100 percent symptom resolution. A 2025 IV pilot by Lee and Burgess confirmed tolerability up to 20 mg intravenous in two adults.
Community data adds a different kind of evidence. Across r/Peptides, ExcelMale, and Longecity, users have reported steady outcomes for years. Pain reduction and improved mobility within 1 to 3 weeks for soft tissue injuries. Gut symptom relief within days on oral dosing. Faster post-surgical recovery. The community figured out the standard protocol before the researchers caught up. 250 mcg subcutaneous twice daily, near the injury, for 4 to 6 weeks.
BPC-157 has no FDA approval. The FDA placed it on the Category 2 bulk drug substance list in 2023, blocking compounding. Its nominators withdrew it, and FDA's Category 2 page (current as of April 22, 2026) lists it as withdrawn. FDA's Pharmacy Compounding Advisory Committee (PCAC) discussed BPC-157 on July 23, 2026. No FDA rule has added it to the 503A bulks list, so compounding pharmacies cannot use it today.
Compared to TB-500, BPC-157 targets local tissue repair near the injection site through angiogenesis and NO modulation. TB-500 works systemically regardless of injection location. The two are commonly paired in a 1:1 ratio for combined local and systemic coverage.
How BPC-157 Works
BPC-157 works through several repair pathways at once. That overlap is part of why it turns up across so many injury models.
The primary mechanism is angiogenesis. BPC-157 upregulates vascular endothelial growth factor (VEGF), triggering new blood vessel formation at injury sites. More capillaries mean better oxygen and nutrient delivery to damaged tissue. This effect is documented across multiple independent labs.
BPC-157 also modulates nitric oxide synthesis, shifting the NO system toward tissue protection. In the gut, this translates to mucosal repair and reversal of NSAID-induced damage. Sikiric and colleagues mapped this pathway extensively [2].
For tendons and ligaments, BPC-157 activates the FAK-paxillin signaling cascade. This pathway controls how cells attach to the extracellular matrix and migrate into damaged areas. That process is rate-limiting in tendon healing.
In rats, BPC-157 interacts with dopamine systems [3] and shifts brain serotonin synthesis [5]. This dual modulation likely explains the neuroprotective effects in animal models and the neuropsychiatric side effects some users report at higher doses.
Growth hormone receptor upregulation adds another layer. In rat tendon cells, BPC-157 appears to sensitize tissue to circulating growth hormone, which may contribute to the tissue remodeling users describe.
BPC-157 Benefits
- BPC-157 benefits center on tissue repair, gut healing, and neuroprotection across over 180 published studies and thousands of community reports.
- Tendon and ligament healing in many animal models; in a 2026 rat Achilles trial [4], BPC-157 alone trended better without reaching significance. Community users consistently report functional improvement within 2 to 4 weeks of daily subcutaneous injection near the injury site.
- Gut lining repair in rat models of NSAID damage, ulcers, and bowel injury. Community users with leaky gut or IBS symptoms on oral dosing (500 to 1,000 mcg fasted) often report relief within the first week.
- Angiogenesis promotion through VEGF upregulation at injury sites in animal and cell studies. An independent Taiwanese lab tied it to VEGFR2 activation [7], not only the Sikiric group.
- Neuroprotective effects in animal models of nerve crush, traumatic brain injury, and spinal cord damage. Community reports of faster nerve recovery after compression injuries match this preclinical data.
- Stability in gastric juice is a rare trait for any peptide. Oral bioavailability has never been measured, but rat studies support an oral route for gut applications.
- The Wolverine Stack (BPC-157 plus TB-500) is the most popular peptide combination in the community. It pairs local tissue repair with systemic healing support.
BPC-157: Science vs Community Consensus
Strong preclinical evidence across 180+ PubMed papers (tendons, ligaments, gut mucosa, nerves, muscle).
Read the evidence (key study, limitations)
Human data is extremely limited: ~30 subjects across all published studies. 2025 systematic review (Vasireddi et al.) found 35 preclinical + 1 clinical study from 544 screened. 2025 IV pilot (Lee & Burgess, n=2) showed tolerability up to 20 mg IV. 2024 intravesical interstitial cystitis series (n=12, 80-100% symptom resolution). PLIVA ran phase 1 and phase 2 ulcerative colitis trials in the early 2000s, but their results appeared only as short conference write-ups, never as full papers (FDA BPC-157 briefing). No published oral bioavailability data in humans.
Vasireddi et al. 2025, "Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review," HSS J. PMID 40756949 / PMC12313605: screened 544 papers, 36 met inclusion, 35 preclinical + 1 clinical; consistent positive musculoskeletal outcomes across animal models; authors recommend caution given evidence quality
No fully published Phase II/III human trial: PLIVA's early-2000s phase 1 and phase 2 ulcerative colitis trials reported results only in conference abstracts (FDA BPC-157 briefing). FDA's 2026 review found five small human studies, about 80 people in all; the three published pilots cover about 30. About 75% of PubMed records for BPC-157 (175 of 233 on Oct 13, 2026) list Sikiric as an author: limited independent replication. No BPC-157 trial has posted results on ClinicalTrials.gov. The 2015 Phase I PCO-02 trial (NCT02637284) last reported "active, not recruiting" in December 2015. Oral bioavailability never quantified in humans. IM bioavailability: 14-19% (rats) vs 45-51% (dogs): human figure unknown. Long-term safety unknown. FDA Category 2 classification (2023-2026) cited immunogenicity risk and insufficient characterization of peptide impurities in compounded preparations. FDA's Category 2 page (current as of April 22, 2026) lists BPC-157 as withdrawn by its nominators; PCAC discussed it on July 23, 2026.
The most widely discussed healing peptide online.
Read the reports (what users report 6, common issues 7)
Standard protocol (250 mcg 2x/day SC near injury) dominates community consensus. Most users report measurable improvement in soft tissue injuries within 1-3 weeks. Gut healing via oral route (500-1,000 mcg fasted) frequently reported effective within days to 2 weeks. Side effects are real but polarized: most tolerate it well at standard doses; a meaningful minority report anxiety, panic attacks, and mood changes, especially above 500 mcg/day or with SSRI/SNRI use.
- Tendon and ligament recovery: many users report return to training within 3-4 weeks
- Gut symptom relief (bloating, NSAID-induced GI damage, IBS flares) on oral protocol: often within first 1-2 weeks
- Reduced joint pain and morning stiffness
- Accelerated post-surgical wound healing when started 1-2 days post-op
- Improved skin healing and reduced scarring at wound sites
- Pain reduction often reported within 24-48 hours of first injection (analgesic/NO effect)
- Anxiety and panic attacks: most commonly reported serious side effect, especially >500 mcg/day
- Heart palpitations, particularly in the first few days of a new cycle
- Mood changes: anhedonia, emotional blunting, or irritability in a subset of users
- Insomnia and vivid dreams
- Brain fog at higher doses (>750 mcg/day)
- Nausea: more common with oral dosing
- Zero effect in some users: most often attributed to product quality/purity issues (purity range: 82-100% per Finnrick Analytics)
Science and community agree on core healing mechanisms (angiogenesis, collagen synthesis, gut repair). Divergence: community doses (250-500 mcg/day) were never validated in a human dose-finding trial. Community widely reports neuropsychiatric side effects (anxiety, panic, anhedonia) that barely appear in preclinical literature: animal models cannot self-report mood effects. The modulation documented in rat studies of dopamine (PMID 9073154) and serotonin (PMID 15531385) provides plausible mechanistic basis for community-reported mood effects.
BPC-157 Dosage Guide
All dosing is community-driven. No human dose-finding trial has been completed. The tiers: beginner 250 mcg twice daily, moderate 500 mcg once daily, aggressive 500 mcg twice daily. All subcutaneous. For gut healing, 500 mcg oral once daily on an empty stomach.
Reconstitution: 5 mg vial with 2 mL bacteriostatic water gives 2.5 mg per mL. Each 10 units on a U-100 insulin syringe equals 250 mcg. A 10 mg vial with 2 mL: each 5 units equals 250 mcg. Add water along the vial wall; swirl, never shake.
Inject as close to the injury as you can. For gut applications, take orally on an empty stomach and wait 30 minutes. Cycle 4 to 6 weeks on, 2 weeks off. Refrigerate reconstituted vials at 2 to 8 degrees Celsius; use within 3 to 4 weeks.
BPC-157 is prohibited under WADA S0 in and out of competition.
Cycling Protocol
Most users run 4-6 week cycles targeted at a specific injury. Can be repeated as needed after a brief break.
No established receptor desensitization mechanism for BPC-157. No published evidence of antibody formation in the limited human data. Cycling is precautionary: BPC-157 continuously stimulates angiogenesis (VEGF pathway), which could theoretically support tumor microvasculature in an oncologic context. Zero long-term human safety data exists. The 4-6 weeks on / 2 weeks off convention is entirely community-derived and not validated in any clinical trial.
- Injury fully healed: no therapeutic rationale to continue
- Onset of anxiety, panic attacks, or mood changes: consider cycling off early
- Heart palpitations persisting beyond the first week of a cycle
- Diminishing returns after Weeks 4-5 without new injury stimulus
Or use the universal Peptide Calculator for any peptide.
BPC-157 Protocols by Goal
Expected: Reduced pain and inflammation Days 1-7. Improved range of motion Weeks 2-3. Significant functional recovery by Weeks 4-6 for most soft tissue injuries. Chronic tendinopathies may require 2-3 cycles.
Monitor: No bloodwork required at standard doses. Track pain (VAS 0-10) and range of motion weekly. If anxiety, palpitations, or mood changes develop, reduce to 1x/day or discontinue.
Who Uses BPC-157?
500mcg recommended dosage, 10 AM/PM daily, 8 weeks on / 8 weeks off.
How to Use BPC-157
- 1Step 1
Gather: BPC-157 vial (5 mg or 10 mg lyophilized), bacteriostatic water, alcohol swabs, insulin syringes (29 to 31 gauge, U-100).
- 2Reconstitute: wipe both vial tops with alcohol
Draw 2 mL bacteriostatic water. Inject into the BPC-157 vial slowly along the glass wall; do not spray onto the powder. Swirl gently. Solution should be clear. Discard if cloudy.
- 3Step 3
Calculate your dose: 5 mg vial with 2 mL BAC water means 10 units equals 250 mcg. A 10 mg vial with 2 mL means 5 units equals 250 mcg.
- 4Draw: insert needle, invert vial, pull to the correct mark
Tap out air bubbles.
- 5Step 5
Inject subcutaneously: pinch skin near the injury at 45 degrees, insert, release pinch, inject slowly. For gut healing, squirt the dose under your tongue or swallow on an empty stomach.
- 6Rotate sites within the target area
For systemic abdominal dosing, alternate left and right lower abdomen.
- 7Refrigerate the reconstituted vial (2 to 8 degrees Celsius)
Use within 3 to 4 weeks. Do not freeze.
Alternative Routes
Reference route: no adjustment needed; community doses (250-500 mcg) are based on SC
Near-injury injection for local effects; abdomen for systemic/gut. Human SC bioavailability unknown; IM bioavailability in rats 14-19%, dogs 45-51%.
Same dose as SC; IM Tmax was 3 min in rats and 6 to 9 min in dogs (He et al. 2022); the study did not test SC
Less community-preferred than SC: SC is equally effective and less painful. No evidence IM outperforms SC for injury healing outcomes.
Community doses 500-1,000 mcg/day oral vs. 250-500 mcg/day SC: higher dose compensates for unquantified oral bioavailability loss
BPC-157 is uniquely acid-stable among peptides: survives gastric transit. Oral bioavailability has never been quantified in humans or published animal PK studies. For gut healing, direct mucosal contact is part of the mechanism. For musculoskeletal injury, SC remains preferred.
2025 pilot: 10-20 mg IV in clinical setting: far above community SC doses; not applicable to self-use protocols
Lee & Burgess 2025 (PMID 40131143): n=2 healthy adults, up to 20 mg IV over 1 hour, no adverse events, no biomarker changes. Clinical-only route. Risk of infection, air embolism, and anaphylaxis precludes self-administration.
BPC-157 Stacking Protocols
Works With
BPC-157 provides targeted local repair at the injury site; TB-500 acts systemically to reduce inflammation and drive cell migration body-wide. Together they cover local + systemic healing: the "Wolverine Stack." Most popular injury-recovery combination in the peptide community.
BPC-157 250-500 mcg/day SC near injury + TB-500 2.5 mg 2x/week SC anywhere. 4-8 weeks loading, then half-frequency maintenance.
GHK-Cu promotes collagen synthesis, skin healing, and anti-aging tissue remodeling. Stacked with BPC-157 to optimize quality of new collagen and reduce scarring during structural repair.
BPC-157 250 mcg 2x/day SC near injury + GHK-Cu 1-2 mg/day SC. GHK-Cu sometimes used topically at wound site alongside systemic BPC-157.
Ipamorelin pulses growth hormone, augmenting systemic anabolic and tissue repair capacity. Community rationale: BPC-157 targets the injury locally; ipamorelin elevates the GH environment for faster overall recovery. No human combination data exists.
BPC-157 250 mcg 2x/day SC + Ipamorelin 200-300 mcg SC 30-60 min pre-sleep.
Avoid
In rats, BPC-157 modulates dopamine pathways (PMID 9073154) and brain serotonin synthesis (PMID 15531385). Multiple community reports document worsened anxiety, agitation, and mood instability when combining with antidepressants. No human interaction study exists. Mechanistic basis is plausible; risk is not quantified.
BPC-157 may modulate coagulation pathways (also listed under its drug interactions). Potential additive effect on bleeding risk with anticoagulants. No human evidence; precautionary.
Anti-VEGF drugs mechanistically oppose BPC-157's primary angiogenic action (VEGF upregulation). Combining is pharmacologically contradictory and would likely reduce therapeutic effect of both.
Do not combineHow much does BPC-157 cost?
Typical price
$4.45 to $6.50 per mg
Middle half of 128 US prices for 10 mg vials · read Oct 31
Free account. Not a pharmacy price: these are vials sold online, and none is an FDA-approved medicine.
Pricing updated 2026-04-09
BPC-157 Side Effects
FDA's 2026 review counted five small human studies, about 80 people in all; the three published pilots cover about 30 of them. The published literature calls it well-tolerated. That is accurate for what it covers; it just does not cover much.
At standard doses (250 to 500 mcg per day), most users report no problems. The side effect picture changes above 500 mcg per day and in people on SSRIs or SNRIs.
Anxiety and panic attacks are the most commonly reported serious community side effects. In rats, BPC-157 interacts with dopamine and adrenergic systems (Sikiric and colleagues)[3] and shifts brain serotonin synthesis [5]. Users with pre-existing anxiety disorders and those on serotonergic medications report the highest rates of this effect.
Heart palpitations show up repeatedly in community reports, typically in the first few days of a cycle. They tend to clear within a week.
Mood changes, including anhedonia, irritability, and a vague sense of feeling "off," affect a subset of users. These track with the dopaminergic and serotonergic modulation in preclinical work. They are more common at higher doses.
Insomnia and vivid dreams come up occasionally. Brain fog above 750 mcg per day appears in community reports with no preclinical correlate. Nausea is more frequent with oral dosing.
Some users report zero effect. Product quality is the usual explanation. Finnrick Analytics tested 450 samples from 64 companies; purity ranged from 82 to 100 percent, with 8 percent of samples containing endotoxin contamination.
Contraindications: pregnancy and breastfeeding (no reproductive data), active cancer or cancer history (angiogenesis could theoretically feed tumor growth), children under 18 (no pediatric data). The SSRI/SNRI interaction risk warrants a conversation with your prescriber.
Common Issues & Solutions
Anxiety or panic attacks: drop immediately to 250 mcg 1x/day; if symptoms persist beyond 48h, discontinue entirely. Do not increase dose later. If on SSRIs/SNRIs, treat as a contraindication.
Heart palpitations in first 3 days: usually transient; reduce dose and monitor. If palpitations persist beyond 3-4 days or are accompanied by chest tightness or dyspnea, discontinue and seek medical evaluation.
No effect after 2+ weeks: verify product purity via independent COA (mass spectrometry preferred); confirm reconstitution math; consider switching to SC injection if using oral for musculoskeletal injury; confirm injection is placed near the injury.
Injection site pain, swelling, or redness: rotate sites within the target area (1-2 inches). Use a fresh needle every injection. Confirm bac water and peptide are fully dissolved before drawing. Check needle gauge (29-31G recommended).
Worsening pain or stiffness in first 3-5 days: a transient pro-inflammatory healing response is plausible. Monitor closely; if it persists beyond day 5 or is severe, stop and reassess.
Ask AI about this page
Ask AI for a second opinion on BPC-157 dosing and side effects
Contraindications
- Pregnancy or breastfeeding (no reproductive safety data available)
- Active cancer or history of cancer (BPC-157 promotes angiogenesis, which could theoretically support tumor growth)
- Children and adolescents (no pediatric safety data)
- Known hypersensitivity to BPC-157 or related peptides
Drug Interactions
- Anticoagulants and antiplatelets: BPC-157 may modulate coagulation pathways; use caution with warfarin, heparin, or aspirin
- NSAIDs: BPC-157 counteracts NSAID-induced GI damage, which may alter expected NSAID gastric side-effect profiles
- Dopaminergic and adrenergic medications: BPC-157 interacts with dopamine and adrenergic systems, potentially modifying drug effects
- Anticoagulants / Antiplatelets (Warfarin, Heparin, DOACs, high-dose Aspirin)
Product Quality
Research-only market with no pharmaceutical manufacturing oversight. Compounding legally prohibited in the US (FDA Category 2 from 2023; listed as withdrawn by its nominators as of April 22, 2026; no 503A bulks rule since). All supply is research-grade product. Independent purity testing (Finnrick Analytics, 450 samples across 64 companies) found purity ranging from 82% to 100%: significant variability. FDA concerns on file include peptide impurities, inadequate characterization, and immunogenicity risk from inconsistent synthesis. Budget products carry the highest quality risk.
- An independent COA carries more weight than an in-house test. Mass spectrometry confirmation of molecular weight is more reliable than HPLC purity alone.
- Products without a third-party COA, or with peptide purity below 95%, carry the highest quality risk.
- Zero-effect responses are frequently a product quality or underdosing problem, not a pharmacological failure: verify source before concluding BPC-157 doesn't work.
- Reconstitute carefully: inject BAC water slowly down the inside vial wall (do not spray directly onto lyophilized powder), swirl gently, never shake. Store reconstituted vials at 2-8°C, use within 3-4 weeks.
- Third-party testing databases publish batch results; a single result describes one lot, not a brand.
Recommended Monitoring
| Test | When | Target |
|---|---|---|
| Injury functional assessment (pain VAS + range of motion) | Weekly throughout active cycle | Progressive improvement; VAS pain <3/10 by end of cycle for successful outcomes |
| Mood and anxiety self-assessment | Daily during first 2 weeks, then weekly | No clinically meaningful change from baseline. Any worsening triggers dose reduction or discontinuation. |
| Basic Metabolic Panel (BMP) + CBC | Baseline + Week 4 for users running >500 mcg/day or multiple consecutive cycles | Within normal reference ranges |
Healing progress is the primary outcome. No biomarker confirms tendon/ligament healing in a community setting: pain scale and functional assessment are the practical endpoints.
BPC-157 modulates serotonin and dopamine pathways. Anxiety, panic, anhedonia, and mood changes are the most common serious adverse effects. Early detection prevents prolonged side-effect exposure.
No evidence-based requirement exists. Precautionary given zero long-term human safety data. The 2025 IV pilot (Lee & Burgess, n=2) found no changes in cardiac, hepatic, renal, thyroid, or glucose markers: but this was n=2 over 2 days, not sustained community-use dosing.
BPC-157 Before and After
Peptide begins modulating nitric oxide and growth factor pathways. No visible changes yet. Reduced pain at injury site reported anecdotally.
Early healing response underway. Reduced inflammation and pain around injury. Gut-related improvements (reduced bloating, discomfort) may begin.
Noticeable improvement in tendon/ligament mobility and pain levels. Gut lining repair progressing. Angiogenesis supporting tissue remodeling.
Significant functional recovery for most soft tissue injuries. Gut symptoms substantially improved. End of typical cycle: assess and consider a 2-week break before repeating.
What to Expect
Days 1 to 3: BPC-157 begins modulating nitric oxide and growth factor pathways. Plasma half-life is 5 to 15 minutes after an IV dose in dogs and rats, and under 30 minutes after IM dosing; no study has measured how long its tissue effects last. Most users notice nothing visible yet. Some report subtle pain reduction near the injection area within a day or two. That is likely an analgesic effect from NO modulation, not structural healing.
Weeks 1 to 2: Inflammation and pain around the injury typically decrease. Gut protocol users often notice the first improvement during this window (reduced bloating, less discomfort). Most first-cycle side effects (palpitations, nausea) have resolved by end of week 2. Anxiety and mood effects, where they occur, tend to peak here.
Weeks 3 to 4: Functional improvement becomes noticeable. Tendon and ligament mobility improves; pain continues to drop. Gut users report sustained symptom control. The angiogenesis triggered in earlier weeks is now supporting active tissue remodeling.
Weeks 5 to 6: Most users with soft tissue injuries report meaningful functional recovery. Gut symptoms are typically well controlled. End of a standard cycle. Take a minimum 2-week break. Chronic tendinopathies or severe injuries may need 2 to 3 cycles total.
Detailed Timeline: Science vs Community
Nitric oxide modulation begins within hours of first dose. VEGF upregulation and FAK-paxillin pathway activation initiated. ERK1/2 phosphorylation and AKT expression elevated in preclinical models. No measurable structural repair yet.
Subjective pain reduction often reported within 24-48 hours: likely analgesic/NO effect rather than structural healing. Many users notice improved sleep quality at the injury site. First-injection anxiety and palpitations peak in this window.
Anti-inflammatory cytokine suppression (COX-2, IL-6, TNF-α). Angiogenesis begins: new capillary formation at injury site. Gut mucosal repair accelerates for oral protocols (direct mucosal contact).
Reduced swelling and tenderness at injury. Gut users report bloating and discomfort improvement. Most side effects (palpitations, nausea) have resolved or become manageable by end of Week 2.
Angiogenesis drives improved nutrient delivery to damaged tissue. Collagen synthesis and tendon fibroblast activity elevated. Growth hormone receptor upregulation in tendon fibroblasts (PMC6271067) amplifies repair signaling.
Noticeably improved range of motion. Significant pain reduction with movement. Many users return to light training. Gut protocol users often report near-complete resolution of chronic GI symptoms.
Peak angiogenic benefit achieved. Structural tissue integrity improved. Animal studies show healed tissue approaches normal tensile strength at 6 weeks.
Most users report functional recovery for soft tissue injuries. Athletes return to sport. End of standard cycle: 2-week break recommended. Chronic or severe injuries may require a second cycle.
No continued pharmacological activity after clearance. Angiogenesis maturation may continue passively: new capillaries established during the cycle continue to support tissue without further peptide stimulus.
Majority report no regression during off-cycle. Some note continued improvement after stopping: consistent with angiogenesis maturation lag. Re-injury risk assessment before returning to full training load.
Pharmacokinetics
Source: Animal PK data only: after a single IV dose, t1/2 was 5.3 min in dogs and 15.2 min in rats; after IM dosing it stayed under 30 min (He et al., Front Pharmacol 2022, PMID 36588717; FDA July 2026 PCAC briefing). The chart shows the rat IV value. No study has measured how long its tissue effects last.
Pharmacokinetics: Active Dose Over Time
t½ = 15.2 min IV in rats, 5.3 min in dogs; under 30 min after IM; no human dataDisclaimer: This curve is a simplified first-order exponential decay model. Actual pharmacokinetics vary based on injection site, individual metabolism, body composition, and other factors. Half-life values are approximate and based on available preclinical and clinical literature. Many research peptides lack formal human pharmacokinetic studies. This is for educational purposes only, not medical advice.
Molecular Profile
Is BPC-157 Legal?
BPC-157 has no FDA approval for any indication. In the United States it is sold as a research chemical. FDA had placed it in 503A Category 2, its list of bulk drug substances that "may present significant safety risks." For BPC-157, FDA cites possible immunogenicity, peptide-related impurities and little or no safety data for the proposed routes. Its nominators withdrew it, and FDA's Category 2 page (current as of April 22, 2026) lists it as withdrawn. PCAC discussed BPC-157 on July 23, 2026. No FDA rule has added it to the 503A bulks list (21 CFR 216.23).
BPC-157 is prohibited by WADA under category S0, both in competition and out. Athletes subject to testing should not use it.
Rules outside the US differ by country. In the US, BPC-157 is not on the DEA's list of controlled substances (August 2026). Product quality varies; a third-party certificate of analysis with mass spectrometry confirmation is the main record of what a batch contains.
This content is for informational purposes only and does not constitute medical advice. Consult a licensed healthcare provider before starting, stopping, or changing any medication.
Evidence grade: Phase 2 trial (Peptide Evidence Gap, October 2026)
Who Should Consider BPC-157
- Athletes recovering from tendon, ligament, or muscle injuries
- Individuals with gut issues (leaky gut, IBS, NSAID-induced damage)
- Post-surgical patients seeking accelerated wound healing
- People with chronic joint or connective tissue pain
- Individuals recovering from nerve injuries
Related Peptides
What Changed for BPC-157
- Evidence
Corrected Oct 13, 2026: the BPC-157 serotonin line now cites a 2004 rat brain study, not a dopamine paper, per PubMed (PMID 15531385).
Before: BPC-157 modulates both dopamine and serotonin systems in animal studies (cited to PMID 9073154, an adrenergic and dopamine paper) After: In rats, BPC-157 interacts with dopamine and adrenergic systems (PMID 9073154) and shifts brain serotonin synthesis (PMID 15531385)
What this does not mean: The warning is unchanged. Anxiety and mood effects remain community reports, and the rat data only make them plausible. PMID 9073154 still backs the dopamine and adrenergic link.
Source: Life Sci 2004, Effects of pentadecapeptide BPC157 on regional serotonin synthesis in the rat brain (Tohyama, Sikiric and Diksic) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)
- Regulatory
PCAC backed BPC-157 for the 503A bulks list 8-6-1 on Jul 23, 2026, per a law-firm summary; reported from the meeting; FDA has not posted minutes.
What this does not mean: The vote did not add it to the 503A bulks list. FDA must complete notice-and-comment rulemaking first, and no proposed or final rule exists (Federal Register search, Oct 6, 2026).
Source: FDA meeting page, Pharmacy Compounding Advisory Committee, July 23-24, 2026 (content current as of 08/06/2026) (opens in a new tab) · Reported by Law-firm client alert, "Bulk-list bound? PCAC backs majority of peptides in two-day public meeting" (Jul 27, 2026) (opens in a new tab) · Saved copy
- Evidence
In rats, BPC-157 plus TB-500 gave no added Achilles tendon benefit over either peptide alone, per Jt Dis Relat Surg, Jul 23, 2026.
What this does not mean: One small rat study: 8 rats per group, 4 weeks of intraperitoneal injections. It did not test people or the pre-mixed vial, and it does not show the stack slows healing.
Also covers: Wolverine Stack (BPC-157 + TB-500), TB-500
Source: Joint Diseases and Related Surgery 2026, BPC-157 and TB-500 on Achilles tendon healing in rats (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)
- RegulatoryEffective
Nominators withdrew 12 peptides (GHK-Cu for injectable routes only) from 503A category 2, announced Apr 15, 2026, per the FDA 503A categories list.
What this does not mean: Leaving category 2 does not put a peptide on the 503A bulks list or make it eligible for compounding. That takes FDA rulemaking, and none has been proposed (Federal Register search, Oct 6, 2026).
Also covers: KPV, TB-500, MOTS-c, DSIP, Semax, Epithalon, GHK-Cu, LL-37, Dihexa, PEG-MGF, Melanotan II
Source: FDA, Bulk drug substances nominated for use in compounding under section 503A (categories list, updated April 22, 2026; the April 15, 2026 notice version is archived beside it) (opens in a new tab) · Saved copy · Archived snapshot (opens in a new tab)
Peptide Schedule Research TeamReviewed Oct 13, 202622 Citations
References
- [1]Emerging Use of BPC-157 in Orthopaedic Sports Medicine: A Systematic Review (Vasireddi et al., HSS J 2025) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [2]Toxicity by NSAIDs. Counteraction by stable gastric pentadecapeptide BPC 157 (Sikiric et al., Curr Pharm Des 2013) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [3]Pentadecapeptide BPC 157 interactions with adrenergic and dopaminergic systems in mucosal protection in stress (Sikiric et al., Dig Dis Sci 1997) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [4]Effects of BPC-157 and TB-500 on Achilles tendon healing in rats: a histopathological and biomechanical study (Biçer et al., Jt Dis Relat Surg 2026) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [5]Effects of pentadecapeptide BPC157 on regional serotonin synthesis in the rat brain (Tohyama et al., Life Sci 2004) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [6]The Stable Gastric Pentadecapeptide BPC 157 Pleiotropic Beneficial Activity and Its Possible Relations with Neurotransmitter Activity (Sikiric et al., Pharmaceuticals 2024) (opens in a new tab)PubMed (opens in a new tab)Review
- [7]Therapeutic potential of pro-angiogenic BPC157 is associated with VEGFR2 activation and up-regulation (Hsieh et al., J Mol Med 2017) (opens in a new tab)PubMed (opens in a new tab)PubMed
- [8]Regeneration or Risk? A Narrative Review of BPC-157 for Musculoskeletal Healing (Curr Rev Musculoskelet Med 2025) (opens in a new tab)PubMed (opens in a new tab)PubMed
Additional References
- Pharmacokinetics, distribution, metabolism, and excretion of BPC-157 in rats and dogs (He et al., Front Pharmacol 2022) (opens in a new tab)PubMed 36588717PubMed
- Stable gastric pentadecapeptide BPC 157: novel therapy in gastrointestinal tract (Sikiric et al., Curr Pharm Des 2011) (opens in a new tab)PubMed 21548867Review
- Stable gastric pentadecapeptide BPC 157 in trials for inflammatory bowel disease heals ileoileal anastomosis in the rat (Sikiric et al., J Physiol Pharmacol 2007) (opens in a new tab)PubMed 17713731PubMed
- Safety of intravenous infusion of BPC-157 in humans: a pilot study (Lee et al., Altern Ther Health Med 2025) (opens in a new tab)PubMed 40131143PubMed
- PCO-02 (oral BPC-157) Phase I safety and pharmacokinetics trial: status unknown, no results posted (NCT02637284) (opens in a new tab)Clinical Trial
- Effect of BPC-157 on Symptoms in Patients with Interstitial Cystitis: A Pilot Study (Lee et al., Altern Ther Health Med 2024) (opens in a new tab)PubMed 39325560PubMed
- The promoting effect of pentadecapeptide BPC 157 on tendon healing involves tendon outgrowth, cell survival, and cell migration (Chang et al., J Appl Physiol 2011) (opens in a new tab)PubMed 21030672PubMed
- Gastric pentadecapeptide body protection compound BPC 157 and its role in accelerating musculoskeletal soft tissue healing (Gwyer et al., Cell Tissue Res 2019) (opens in a new tab)PubMed 30915550Review
- Brain-gut Axis and Pentadecapeptide BPC 157: Theoretical and Practical Implications (Sikiric et al., Curr Neuropharmacol 2016) (opens in a new tab)PubMed 27138887Review
- BPC 157 and Standard Angiogenic Growth Factors: Gastrointestinal Tract Healing, Lessons from Tendon, Ligament, Muscle and Bone Healing (Seiwerth et al., Curr Pharm Des 2018) (opens in a new tab)PubMed 29998800Review
- Stable Gastric Pentadecapeptide BPC 157 and Wound Healing (Seiwerth et al., Front Pharmacol 2021) (opens in a new tab)PubMed 34267654Review
- Pentadecapeptide BPC 157 counteracts L-NAME-induced catalepsy: BPC 157, L-NAME, L-arginine, NO-relation (Zemba Cilic et al., Behav Brain Res 2021) (opens in a new tab)PubMed 32956773PubMed
- DEA Diversion Control Division: Controlled Substances, alphabetical order (August 27, 2026) (opens in a new tab)Review
- FDA briefing document: BPC-157 for the Pharmacy Compounding Advisory Committee, July 23-24, 2026 (dated May 11, 2026): five small clinical studies, none by subcutaneous injection (opens in a new tab)Review
Related Resources
Related Tools
Further Reading
Storage & Stability
Frequently Asked Questions
How popular is BPC-157?
Hot. A popularity tier (hot, popular, emerging or niche), based on search volume and community activity.
Reddit: 1,000+. Community mentions on Reddit: ~1,000+ threads.
High search interest. A band for how often people search Google for the name each month.
These come from this site's peptide records. They are not live counts.


